Brigham and Women’s Hospital, Boston, Massachusetts
June 2014, Part 2 - Uncategorized
With the recent advancements in the treatment of patients with metastatic melanoma, in particular with immunomodulating therapies, the development of unique immune-related side effects has posed novel management challenges. The first drug in this class to receive FDA approval for the treatment of unresectable stage III or IV melanoma is [ Read More ]
August 2013, Vol 2, No 5 - Immunotherapy
With the recent advancements in the treatment of patients with metastatic melanoma, in particular with immunomodulating therapies, the development of unique immune-related side effects has posed novel management challenges. The first drug in this class to receive FDA approval for the treatment of unresectable stage III or IV melanoma is [ Read More ]
Copyright 2023. Amplity Medical Communications. All Rights Reserved. Privacy Policy. Sitemap.
